Outpace Bio, a Seattle, WA-based cell therapy company using AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, raised $144m in Series B financing.
The Series B financing, which brought the total capital raised to approximately $200m, was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments, and other undisclosed investors, and existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, WRF Capital, and Sahsen Ventures. Jake Simson, PhD, Partner at RA Capital Management has been appointed to the company’s Board of Directors.
Led by Marc Lajoie, PhD, Co-Founder & Chief Executive Officer, Outpace is advancing an internal pipeline of engineered T cell therapies for the treatment of solid tumors.
Proceeds from the financing will be used to advance multiple programmed T cell product candidates to early clinical proof-of-concept for the treatment of solid tumors. The company’s lead program OPB-101 is a mesothelin-specific chimeric antigen receptor (CAR) T cell enhanced by Outpace’s proprietary OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™ technologies, which is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. Additionally, the funds will support the expansion of Outpace’s future pipeline leveraging the company’s plug-and-play technology platform.
FinSMEs
01/08/2024